Groundbreaking research into the accuracy of an AI cancer prediction platform has unveiled a significant achievement: it correctly identified the risk of cancer type in 93% of cases, potentially marking a pivotal advancement in early cancer diagnosis.
The study, involving an analysis of 100,000 patients, is set to be published in full in the coming months and sought to assess the accuracy of C the Signs in predicting the origin of cancer for patients within a real-world healthcare setting.
C the Signs is a clinical platform that seamlessly integrates with electronic health records (EHR) and utilises artificial intelligence to assist in identifying patients at risk of cancer.
Early analysis of the study’s findings suggests that cancer prediction platforms like C the Signs can effectively and accurately pinpoint the origin of tumours in patients presenting with vague symptoms. This capability can facilitate targeted investigations tailored to the specific type of tumour.
The preliminary findings were presented in an oral presentation at the American Society of Clinical Oncology Quality Care Symposium in Boston on October 28.
Dr. Bea Bakshi, Co-founder of C The Signs, expressed their delight, stating, “We were delighted to present the initial findings of our study, which has shown promising results for the effectiveness of our C the Signs AI technology. Our technology is already being used by over 10,000 healthcare professionals, and while further research is required to identify which cancers can be most accurately detected taking a computational approach, we are very optimistic about these initial findings and firmly believe that they could revolutionise the way cancer risk is assessed in the future.”
C the Signs is used by primary care physicians (PCPs) during point-of-care assessments. It analyses the patient’s symptoms, along with clinical data from the EHR, to identify current cancer risk, predict the site of origin of the tumour, and recommend the most suitable diagnostic or referral pathway.
For further information, please visit cthesigns.co.uk.
